ENDACEA
Endacea, Inc. (RTP, NC), an emerging biopharmaceutical company, is developing a series of proprietary A1 adenosine receptor (AR) antagonists as drug candidates for a number of medical indications: 1) inflammation, including sepsis and asthma; and 2) renal impairment. Endacea is advancing the Company's lead compound A1 AR antagonist, L-97-1, as an i.v. anti-sepsis drug candidate and as a post-exposure medical countermeasure for plague and other biodefense indications. Endacea is also developing an endotoxin assay as a sensitive and specific biomarker to detect patients with or at risk of sepsis and for other uses. Endacea recently formed a subsidiary, Endacea Diagnostics, Inc. to develop this assay.
ENDACEA
Industry:
Biotechnology Health Diagnostics Pharmaceutical
Address:
Davis, California, United States
Country:
United States
Website Url:
http://www.endacea.com
Total Employee:
1+
Status:
Active
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Apple Mobile Web Clips Icon WordPress Font Awesome Wordpress Plugins Sitelinks Search Box
Similar Organizations
Acasti Pharma
Acasti Pharma is an emerging biopharmaceutical company.
Current Employees Featured
Founder
Official Site Inspections
http://www.endacea.com Semrush global rank: 5.39 M Semrush visits lastest month: 1.56 K
- Host name: 205.178.133.10
- IP address: 205.178.133.10
- Location: Jacksonville United States
- Latitude: 30.1426
- Longitude: -81.5727
- Metro Code: 561
- Timezone: America/New_York
- Postal: 32258
More informations about "Endacea"
Biopharmaceutical Research and Development
This is the aim of ENDACEA (RTP, NC) – to connect scientific expertise with medical technologies to design life-changing solutions. Since 1996, it has been at the forefront of biopharmaceutical research and development and continues to …See details»
Endacea Home Page
Endacea is advancing the Company's lead compound A 1 AR antagonist, L-97-1, as an i.v. anti-sepsis drug candidate and as a post-exposure medical countermeasure for plague and other …See details»
Endacea - Crunchbase Company Profile & Funding
Endacea, Inc. (RTP, NC), an emerging biopharmaceutical company, is developing a series of proprietary A1 adenosine receptor (AR) antagonists as drug candidates for a number of …See details»
Leadership ENDACEA | ENDACEA
ENDACEA’s leadership, along with its partners and shareholders, are accountable for the company’s continued research and development success. Since 1996, it has been committed …See details»
Endacea, Inc Company Profile - Dun & Bradstreet
Endacea, Inc Company Profile | Research Triangle Park, NC | Competitors, Financials & Contacts - Dun & BradstreetSee details»
Endacea, Inc. - Contact Us
Endacea, Inc. - Contact Us Management: Constance Neely Wilson, M.D. President and Chief Executive Officer Chief Scientific Officer 919-406-1888 x1400. Email: cwilson @ endacea.com …See details»
Endacea - Contacts, Employees, Board Members, Advisors & Alumni
Endacea is an emerging biopharmaceutical company. Start Free Trial . Chrome ExtensionSee details»
Endacea, Inc. - About Us
Endacea is a development stage biopharmaceutical company with a proprietary A1 adenosine receptor based technology platform for the treatment of asthma, ischemia-reperfusion organ …See details»
ENDACEA, INC - CAGE.report
ENDACEA INC. Company Details. Identification, Location & Contacts This profile was last updated: 07/30/2019 Status: Active User ID: P0708811 Name of Firm: ... Organization, …See details»
Endacea, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Explore Endacea, Inc. with its drug pipeline, therapeutic area, technology platform, , Disease Domain:Neoplasms, Infectious Diseases, Technology Platform:Chemical ...See details»
Endacea Company Profile - Office Locations, Competitors ... - Craft
Endacea is a biopharmaceutical company. It develops a proprietary A1 adenosine receptor-based technology platform for the treatment of asthma, ischemia-reperfusion organ injury, and Gram …See details»
Endacea Inc, Durham NC - Company Profile - BizStanding
A registered office address is 2 Davis Dr, Durham, NC 27709. Call the organization at phones: (919) 406-1888 or (919) 406-1838. Who has worked at Endacea Inc. Position at Endacea Inc …See details»
ENDACEA, INC. - VentureRadar
Endacea, Inc., an emerging biopharmaceutical company, is developing a series of proprietary A1 adenosine receptor (AR) antagonists as drug candidates for a number of medical indications. …See details»
Endacea - Products, Competitors, Financials, Employees, …
Endacea is a biopharmaceutical company focused on research and development within the healthcare sector. Use the CB Insights Platform to explore Endacea's full profile. Endacea - …See details»
Endacea - Overview, News & Similar companies | ZoomInfo.com
Who is Endacea. Endacea, Inc. (RTP, NC), an emerging biopharmaceutical company, is developing a series of proprietary A1 adenosine receptor (AR) antagonists as dru g candidates …See details»
Endacea Inc. | North Carolina Biotech Center
Endacea develops A1 adenosine receptor antagonists as drug candidates for acute lung injury, sepsis and acute renal failure. Endacea is also developing a novel immunotherapy, mutant …See details»
Endacea, Inc. - Science
Endacea is a development stage biopharmaceutical company with a proprietary A1 adenosine receptor based technology platform for the treatment of asthma, ischemia-reperfusion organ …See details»
Don Wilson - President and CEO - Endacea Diagnostics, Inc.
CEO, Endacea, Inc. · Experience: Endacea Diagnostics, Inc. · Education: Harvard Law School · Location: Durham · 125 connections on LinkedIn. View Don Wilson’s profile on LinkedIn, a ...See details»
Biopharmaceutical Pipeline | ENDACEA
ENDACEA’s lead compound A1 adenosine receptor (AR) antagonist, L-97-1, is a “best in class” A1 AR antagonist. This compound has a high affinity and selectivity for the human A1 AR, is a …See details»
Enercea
Imagine a future where your home generates its own power, eliminating utility bills forever. At Enercea, we are redefining what it means to live sustainably, blending cutting-edge technology …See details»